Drug Overview
Trelegy Ellipta 100/62.5/25 mcg Inhalation Powder is a prescription-only maintenance inhaler that combines three medicines in one device to support long-term control of chronic respiratory symptoms. It is used to help improve breathing, reduce airway narrowing, and provide ongoing symptom relief in patients with chronic obstructive pulmonary disease (COPD), and it may also be prescribed in selected asthma cases under medical supervision. This medicine requires a valid and up-to-date prescription before dispensing.
Active Ingredient and Composition
This inhaler contains three active ingredients:
- Fluticasone furoate – an inhaled corticosteroid that helps reduce airway inflammation
- Umeclidinium bromide – a long-acting muscarinic antagonist (anticholinergic) that helps keep the airways open
- Vilanterol trifenatate – a long-acting beta2 agonist that helps relax bronchial muscles and improve airflow
The product is supplied as a dry powder inhaler using the Ellipta device and is available as 30 inhaled doses.
Drug Class
Combination respiratory maintenance therapy: inhaled corticosteroid + long-acting muscarinic antagonist + long-acting beta2 agonist.
Uses and Medical Indications of Trelegy Ellipta
Trelegy Ellipta 100/62.5/25 mcg is used as a maintenance treatment to support patients with chronic airway disease, especially those who need triple-action inhalation therapy. It may help with:
- Long-term management of COPD
- Relief of persistent respiratory symptoms such as shortness of breath, wheezing, and chest tightness
- Improvement of airflow in patients with chronic bronchitis or obstructive lung disease
- Maintenance control of asthma in patients when prescribed by a physician
It is intended for ongoing control and not as a rescue treatment for sudden breathing attacks.
How Trelegy Ellipta Works
Trelegy Ellipta works through a triple-mechanism approach. Fluticasone furoate lowers inflammation inside the airways, umeclidinium reduces bronchial constriction by blocking muscarinic receptors, and vilanterol relaxes airway smooth muscle to improve airflow. Together, these actions help reduce breathing difficulty, support lung function, and improve daily respiratory control.
Dosage and Administration of Trelegy Ellipta
- Usual use: One inhalation once daily as prescribed
- Route: Oral inhalation through the Ellipta device
- Instructions: Inhale the dose directly from the inhaler using the device correctly
- Important: Use at the same time each day for consistent maintenance benefit
Trelegy Ellipta 100/62.5/25 mcg should be used exactly as directed by the treating physician. Do not stop treatment suddenly without medical advice.
Possible Side Effects
Some patients may experience mild and temporary side effects, including:
- Headache
- Sore throat
- Dry mouth
- Hoarseness or voice changes
- Upper respiratory tract infections
If symptoms worsen, become persistent, or are accompanied by severe breathing difficulty, medical attention is needed.
Contraindications
- Known hypersensitivity to any of the active ingredients or formulation components
- Use without medical supervision in patients with unstable respiratory disease
Drug Interactions
Caution is advised when this inhaler is used together with other respiratory medicines or long-term therapies that may affect heart rhythm, breathing control, or anticholinergic burden. Patients should inform the physician about all inhalers, prescription medicines, and supplements they use regularly.
Warnings and Precautions
- Use only under medical supervision
- Not suitable for sudden acute breathing attacks
- Use cautiously in patients with heart disease
- Take special care in poorly controlled asthma
- Do not discontinue abruptly unless your doctor advises it
Use During Pregnancy and Breastfeeding
This inhaler should be used during pregnancy or breastfeeding only when clearly needed and after a doctor evaluates the expected benefit versus potential risk. Self-medication is not recommended.
Use for Children
This product should only be used in the age group and indication approved by the treating physician. Pediatric suitability must be assessed individually based on diagnosis and prescribed treatment plan.
Drug Alternatives
Therapeutic alternatives may include other maintenance inhalers used for COPD or asthma control, such as:
- Dual bronchodilator inhalers
- ICS/LABA combination inhalers
- Other triple-combination maintenance inhalers
The most suitable alternative depends on symptom severity, lung condition, response to therapy, and physician assessment.
Comparison With Similar Drugs
Compared with conventional single- or dual-action inhalers, this formulation provides triple respiratory support in one device. The difference between Trelegy Ellipta 200 and Trelegy Ellipta 100/62.5/25 mcg mainly relates to the corticosteroid strength, and the appropriate option should always be selected by the physician according to the patient’s clinical condition.
Safe Usage Tips
- Stop smoking to improve respiratory outcomes
- Practice breathing exercises when recommended
- Avoid smoke, dust, and other environmental irritants
- Stay adherent to the prescribed maintenance plan
- Store at room temperature away from heat and moisture
- Keep out of the reach of children
In summary, Trelegy Ellipta 100/62.5/25 mcg is a prescription maintenance inhaler that combines anti-inflammatory and bronchodilator actions to help improve breathing and support long-term control of COPD and selected asthma cases.
